Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
As the first SPORE of its kind in the United States, the Mayo Clinic Hepatobiliary SPORE is devoted to improving the diagnosis and treatment of liver cancer (hepatocellular carcinoma) and bile duct cancer (cholangiocarcinoma), which are grouped together as hepatobiliary cancers.
New treatment options for hepatobiliary cancers (hepatobiliary carcinomas) are urgently needed. Five-year survival rates are low, and the death rate is on the rise.
Research in the Hepatobiliary SPORE is driving new discoveries that are providing important insights about the biology of hepatobiliary cancers. Investigators are working on new diagnostic tests, screening treatment compounds, launching new clinical trials, identifying biomarkers and harnessing the power of oncolytic viruses to attack cancer. Research advances in the SPORE can change the trajectory of liver cancer and bile duct cancer, offering optimism for patients facing a sometimes grim prognosis.
The Mayo Clinic Hepatobiliary SPORE builds on significant contributions our investigators have already made to research on liver cancer and bile duct cancer.
Learn about ongoing and upcoming clinical trials, including a study of MTI-301 in patients with advanced malignancy.
Building on significant contributions to science, the SPORE has four translational research projects that focus on hepatobiliary cancer.
Both the Developmental Research Program and the Career Enhancement Program encourage promising investigators by funding pilot projects that advance hepatobiliary cancer research.
The SPORE receives vital support from its Administrative Core, its Biostatistics and Bioinformatics Core, and its Biospecimen and Pathology Core.
Review select publications related to our research in the Mayo Clinic Hepatobiliary SPORE.
Contact us about research projects or to learn about our funding awards and training opportunities for qualified women, people of color, people with disabilities and other promising researchers.